about
Level of inflammatory factors in chronic hemodialysis patients with and without cardiovascular disease.Effect of Omega-3 fatty acids on blood pressure and serum lipids in continuous ambulatory peritoneal dialysis patientsEffects of Oral L-Carnitine Supplementation on Lipid Profile, Anemia, and Quality of Life in Chronic Renal Disease Patients under Hemodialysis: A Randomized, Double-Blinded, Placebo-Controlled TrialSalivary levels of interleukin-6 and tumor necrosis factor-α in patients undergoing hemodialysis.Oxford-MEST classification in IgA nephropathy patients: A report from Iran.Granulomatosis with polyangiitis (Wegener's) presenting as the right ventricular masses: A case report and review of the literature.The impact of oat (Avena sativa) consumption on biomarkers of renal function in patients with chronic kidney disease: A parallel randomized clinical trial.Limited knowledge of chronic kidney disease and its main risk factors among Iranian community: an appeal for promoting national public health education programs.Evaluation of serum levels of lipids and lipoproteins in kidney-transplanted patients.Down-regulation of inflammatory signaling pathways despite up-regulation of Toll-like receptors; the effects of corticosteroid therapy in brain-dead kidney donors, a double-blind, randomized, controlled trial.Cardiovascular risk and mortality in end-stage renal disease patients with restless legs syndrome; need for further investigation and looking for underlying mechanisms.Relationship between renal volume calculated by using multislice computed tomography and glomerular filtration rate calculated by using the Cockcroft-Gault and modification of diet in renal disease equations in living kidney donors.Oxalate nephropathy after Jejuno-Ileal bypass surgery.Aerobic exercise improves signs of restless leg syndrome in end stage renal disease patients suffering chronic hemodialysis.Administration of vitamin E and losartan as prophylaxes in cisplatin-induced nephrotoxicity model in ratsA one-year hospital-based prospective COVID-19 open-cohort in the Eastern Mediterranean region: The Khorshid COVID Cohort (KCC) study
P50
Q33660722-10917540-A804-4A2B-A566-50A31C343E27Q35993374-EC2721C7-ADD8-461A-93D4-2982ACFA73D0Q36031155-DE2A21E8-F732-4909-88DD-8EB64799A7CEQ36628703-7C5AD3B4-9B69-4D8A-8B06-08F0E4E33F26Q37455110-490E499F-7C6F-402F-AAB3-6C641D7504C9Q38182988-1F759CC9-64CC-4676-9057-FE646A5317E9Q38383244-22A8C226-0164-477A-96BE-E25DF60628EEQ39188799-1EB1E7D0-4945-40BC-8E29-8CCC7E64CB53Q43702772-78F5EED7-AB6D-4B8A-990B-9D46A8E95DBCQ47801875-B4177B81-1533-4B15-BE01-480D322655C1Q48199432-CB54738C-EEFE-4990-9FFB-06D401886F9EQ50195916-8A0F4ED6-6E28-4BAB-AC01-A87BC0AD9D1CQ53350704-2655D09F-BC0A-49AD-AE96-CE1A83A39DB3Q54487276-79BB79E4-6423-4F58-AB0C-A0781FC59ABEQ84959808-25ACACC8-22EC-4B44-A7E2-5F6F372AB3CEQ95627920-E95FF9BC-8BF1-4400-9013-56CFD5226B6A
P50
description
researcher ORCID ID = 0000-0002-9636-2553
@en
wetenschapper
@nl
name
Mojgan Mortazavi
@ast
Mojgan Mortazavi
@en
Mojgan Mortazavi
@es
Mojgan Mortazavi
@nl
type
label
Mojgan Mortazavi
@ast
Mojgan Mortazavi
@en
Mojgan Mortazavi
@es
Mojgan Mortazavi
@nl
prefLabel
Mojgan Mortazavi
@ast
Mojgan Mortazavi
@en
Mojgan Mortazavi
@es
Mojgan Mortazavi
@nl
P1153
26635577200
P31
P496
0000-0002-9636-2553